Concepts (102)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adrenomedullin | 10 | 2025 | 82 | 2.240 |
Why?
|
| Peptide Hormones | 8 | 2022 | 68 | 2.040 |
Why?
|
| Placenta | 4 | 2026 | 497 | 1.490 |
Why?
|
| Calcitonin Gene-Related Peptide | 6 | 2021 | 86 | 1.380 |
Why?
|
| Myocytes, Smooth Muscle | 4 | 2022 | 171 | 1.290 |
Why?
|
| Pre-Eclampsia | 2 | 2026 | 226 | 1.230 |
Why?
|
| Receptors, Complement | 1 | 2026 | 34 | 0.950 |
Why?
|
| Complement Activation | 1 | 2026 | 50 | 0.950 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2022 | 44 | 0.840 |
Why?
|
| Uterine Artery | 2 | 2022 | 27 | 0.820 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2021 | 224 | 0.710 |
Why?
|
| Receptor Activity-Modifying Protein 3 | 3 | 2022 | 12 | 0.670 |
Why?
|
| Vesicular Transport Proteins | 1 | 2021 | 138 | 0.630 |
Why?
|
| Omentum | 3 | 2018 | 40 | 0.630 |
Why?
|
| Fetal Growth Retardation | 2 | 2026 | 252 | 0.610 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2016 | 86 | 0.590 |
Why?
|
| Vasodilation | 2 | 2016 | 175 | 0.560 |
Why?
|
| Arteries | 2 | 2016 | 209 | 0.550 |
Why?
|
| Pregnancy | 11 | 2026 | 7456 | 0.480 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2016 | 134 | 0.470 |
Why?
|
| Mucin-1 | 1 | 2015 | 32 | 0.460 |
Why?
|
| Amniotic Fluid | 1 | 2016 | 146 | 0.450 |
Why?
|
| Estrous Cycle | 1 | 2014 | 40 | 0.430 |
Why?
|
| Abortion, Spontaneous | 1 | 2015 | 81 | 0.430 |
Why?
|
| Decidua | 1 | 2015 | 143 | 0.430 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2014 | 82 | 0.420 |
Why?
|
| Nitric Oxide | 2 | 2016 | 465 | 0.420 |
Why?
|
| Vasodilator Agents | 1 | 2015 | 197 | 0.410 |
Why?
|
| Ovulation | 1 | 2014 | 102 | 0.410 |
Why?
|
| Neuropeptides | 1 | 2014 | 106 | 0.410 |
Why?
|
| Embryo Implantation | 1 | 2015 | 218 | 0.400 |
Why?
|
| Peptide Fragments | 1 | 2016 | 687 | 0.370 |
Why?
|
| Ovary | 1 | 2014 | 345 | 0.360 |
Why?
|
| Receptor Activity-Modifying Protein 2 | 3 | 2022 | 12 | 0.330 |
Why?
|
| Receptor Activity-Modifying Protein 1 | 2 | 2022 | 13 | 0.300 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2022 | 33 | 0.300 |
Why?
|
| In Vitro Techniques | 2 | 2022 | 808 | 0.270 |
Why?
|
| Calcitonin Receptor-Like Protein | 3 | 2016 | 21 | 0.270 |
Why?
|
| Diabetes, Gestational | 2 | 2019 | 111 | 0.250 |
Why?
|
| Receptors, Complement 3b | 1 | 2026 | 13 | 0.240 |
Why?
|
| Trophoblasts | 2 | 2016 | 113 | 0.220 |
Why?
|
| Female | 12 | 2026 | 70342 | 0.190 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2025 | 222 | 0.180 |
Why?
|
| Apamin | 1 | 2022 | 4 | 0.180 |
Why?
|
| Charybdotoxin | 1 | 2022 | 8 | 0.180 |
Why?
|
| Receptors, Calcitonin | 1 | 2022 | 21 | 0.180 |
Why?
|
| Dimerization | 1 | 2022 | 137 | 0.180 |
Why?
|
| Hypertension, Pulmonary | 1 | 2025 | 456 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2022 | 1604 | 0.160 |
Why?
|
| Multigene Family | 1 | 2021 | 289 | 0.160 |
Why?
|
| Fetal Macrosomia | 1 | 2018 | 20 | 0.140 |
Why?
|
| Disease Models, Animal | 2 | 2026 | 4642 | 0.140 |
Why?
|
| Insulin-Secreting Cells | 1 | 2019 | 133 | 0.130 |
Why?
|
| Animals | 5 | 2026 | 33676 | 0.130 |
Why?
|
| Bradykinin | 1 | 2016 | 42 | 0.120 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2018 | 235 | 0.120 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2016 | 162 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2548 | 0.120 |
Why?
|
| Chorionic Villi | 1 | 2015 | 20 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2016 | 186 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2018 | 498 | 0.110 |
Why?
|
| Dyslipidemias | 1 | 2018 | 249 | 0.110 |
Why?
|
| Mesenteric Arteries | 1 | 2015 | 50 | 0.110 |
Why?
|
| Pregnancy Trimester, First | 1 | 2015 | 116 | 0.110 |
Why?
|
| Corpus Luteum | 1 | 2014 | 24 | 0.110 |
Why?
|
| Cyclic AMP | 1 | 2015 | 221 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 637 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1589 | 0.100 |
Why?
|
| Receptors, Calcitonin Gene-Related Peptide | 1 | 2014 | 21 | 0.100 |
Why?
|
| Insulin | 1 | 2019 | 1146 | 0.100 |
Why?
|
| Granulosa Cells | 1 | 2014 | 140 | 0.100 |
Why?
|
| Hypoxia | 1 | 2015 | 247 | 0.100 |
Why?
|
| Humans | 10 | 2025 | 130204 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 1109 | 0.090 |
Why?
|
| Pregnancy Complications | 2 | 2018 | 564 | 0.090 |
Why?
|
| Fetal Development | 1 | 2014 | 121 | 0.090 |
Why?
|
| Rats | 2 | 2016 | 3372 | 0.090 |
Why?
|
| Mice | 2 | 2026 | 18173 | 0.090 |
Why?
|
| Inflammation | 1 | 2018 | 1479 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2885 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2016 | 3351 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 2323 | 0.070 |
Why?
|
| Hyperoxia | 1 | 2025 | 136 | 0.050 |
Why?
|
| Adult | 3 | 2019 | 31035 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2025 | 1022 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2025 | 2331 | 0.040 |
Why?
|
| Receptors, Adrenomedullin | 1 | 2019 | 16 | 0.040 |
Why?
|
| Lipolysis | 1 | 2018 | 77 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2019 | 198 | 0.030 |
Why?
|
| Lung | 1 | 2025 | 1532 | 0.030 |
Why?
|
| Receptor Activity-Modifying Proteins | 1 | 2015 | 16 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2019 | 556 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2019 | 695 | 0.030 |
Why?
|
| Lipids | 1 | 2018 | 566 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2019 | 1112 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 2553 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2016 | 1570 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 467 | 0.020 |
Why?
|
| Uterus | 1 | 2016 | 540 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5166 | 0.020 |
Why?
|
| Prognosis | 1 | 2018 | 4847 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 4646 | 0.010 |
Why?
|